Man Group plc Invests $2.43 Million in Elanco Animal Health Incorporated $ELAN

Man Group plc acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 98,839 shares of the company’s stock, valued at approximately $2,432,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Elanco Animal Health during the second quarter valued at approximately $1,202,198,000. Primecap Management Co. CA acquired a new stake in shares of Elanco Animal Health in the second quarter worth $1,118,402,000. The Manufacturers Life Insurance Company bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth $205,636,000. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Finally, Sei Investments Co. grew its stake in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after buying an additional 4,975,721 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $23.91 on Wednesday. The stock has a 50-day simple moving average of $24.63 and a 200 day simple moving average of $23.98. The stock has a market capitalization of $11.95 billion, a price-to-earnings ratio of -58.32, a P/E/G ratio of 1.43 and a beta of 1.68. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the business posted $0.26 earnings per share. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ELAN. KeyCorp boosted their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. TD Cowen raised their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. upped their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Insider Activity at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen bought 4,200 shares of the company’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This represents a 3.15% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul Herendeen bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the transaction, the director owned 111,687 shares in the company, valued at $2,644,748.16. The trade was a 9.83% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 63,198 shares of company stock valued at $1,473,109 over the last 90 days. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.